Biopharma Co.'s Shares Triple in Value on US$5B License Deal
Source: Streetwise Reports  (12/7/22)
Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-license agreement with Akeso Inc. for its breakthrough bispecific antibody ivonescimab, which combines a blockade of PD-1 with an anti-VEGF into a single molecule designed to target cancer. Summit has agreed to pay Akeso an upfront payment of US$500 million, which it plans to finance via an equity rights issuance. More >

Biotech Co.'s Shares Soar to New 52-Week High
Source: Streetwise Reports  (12/7/22)
Prometheus Biosciences Inc. shares traded 170% higher to a new 52-week intraday high after the company reported positive results from two separate Phase 2 clinical studies for its PRA023, an anti-TL1A mAb used to treat inflammatory bowel disease. The company is actively planning to advance PRA023 into Phase 3 trials as a prospective treatment for ulcerative colitis and Crohn's disease in FY/23. More >

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial
Source: Streetwise Reports  (12/5/22)
Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline. More >

Target Price Boosted on Canadian Pharma Co.
Source: Dr. Andre Uddin  (11/30/22)
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report. More >

Biopharma Co. Now at a Bargain Price, Analyst Says
Source: Dr. Andrew Uddin   (11/29/22)
Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report. More >

Major Contract and Faster Commercialization for Chemicals Co.
Source: Penny Queen  (11/29/22)
Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile. More >

Expert Says Health Tech Co. Still in Good Spot To Buy
Source: Clive Maund  (11/28/22)
Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy. More >

Biopharma Co. Trades to New 52-Week High
Source: Streetwise Reports  (11/28/22)
Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints
in the Phase 3 ACCORD Alzheimer's disease agitation trial. More >

Pharma Co. Gains Approval for SARS-CoV-2 Drug
Source: Streetwise Reports  (11/23/22)
Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection. More >

Life Sciences Co. Exceeds Expectations in Q3/22
Source: Dr. Andre Uddin  (11/22/22)
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report. More >

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock
Source: Dr. Yale Jen  (11/22/22)
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report. More >

Global Drug Co. Offers US$1.35B To Boost Hematology Assets
Source: Streetwise Reports  (11/22/22)
Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share. More >

Blockchain Co. Signs Agreement With Insurance Co.
Source: Streetwise Reports  (11/22/22)
Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry. More >

FDA Awards Breakthrough Therapy Status for AMD Drug
Source: Streetwise Reports  (11/21/22)
Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration. More >

Pharma Co. Won't See Bump in Sales From New COVID Drug
Source: Dr. Andre Uddin  (11/18/22)
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report. More >

Biopharma Co. Hopes To Turn US$30M Into US$2B
Source: Streetwise Reports  (11/17/22)
CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types. More >

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data
Source: Streetwise Reports  (11/16/22)
4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration. More >

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment
Source: Streetwise Reports  (11/14/22)
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon. More >

UK Co. Buys NARCAN® Nasal Spray Maker
Source: Streetwise Reports  (11/14/22)
Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met. More >

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says
Source: Streetwise Reports  (11/11/22)
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts. More >

Biologics Co. Doubles Revenue in Q3/22
Source: Streetwise Reports  (11/11/22)
ADMA Biologics Inc. shares traded 27.5% higher yesterday after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million. More >

Pharma Co. Trades 200% Higher
Source: Streetwise Reports  (11/10/22)
Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma. More >

Medical Device Co.'s Q2/22 Results Better Than Expected
Source: Dr. Andre Uddin  (11/9/22)
Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report. More >

Nine Stocks Expert Says Should Pique Your Interest
Source: Clive Maund  (11/9/22)
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on. More >

Clean Nuclear Med Tech With Quantum Blue Sky
Source: Penny Queen  (11/9/22)
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention. More >